EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Exelixis, Inc.

1851 Harbor Bay Parkway
Alameda, CA 94502
United States
650-837-7000
http://www.exelixis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees484

Key Executives

NameTitlePayExercisedYear Born
Dr. Stelios PapadopoulosCo-Founder & Chairman95kN/A1948
Dr. Michael M. MorrisseyCEO, Pres & Director1.95M11.99M1961
Mr. Christopher J. SennerExec. VP & CFO941.31kN/A1968
Dr. Peter LambExec. VP of Scientific Strategy & Chief Scientific Officer813.27kN/A1961
Mr. Jeffrey J. HessekielExec. VP, Gen. Counsel & Sec.842.22k491k1969
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Corporate Governance

Exelixis, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 2. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 5; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.